AP SA 02
Alternative Names: AP-SA-02Latest Information Update: 27 Jan 2026
At a glance
- Originator Armata Pharmaceuticals
- Class Anti-infectives; Antibacterials; Bacteriophages
- Mechanism of Action Cell death stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Staphylococcal infections
- Preclinical Bone and joint infections
- No development reported Bronchiectasis
Most Recent Events
- 13 Jan 2026 Armata Pharmaceuticals concludes an End-of-Phase 2 (EOP2) with the US FDA for AP SA 02
- 13 Jan 2026 Armata Pharmaceuticals submits a request for Qualified Infectious Disease Product Designation (QIDP) for AP SA02 in Staphylococcal infections
- 22 Oct 2025 Efficacy and adverse event data from a phase I/II disarm trial in Staphylococcal infections released by Armata Pharmaceuticals